Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 12, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 2,750,000 ordinary shares of 25 pence each.
- Purchase Price: 1,091.2776 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.16% of total voting rights).
- Shares in Issue: 5,503,563,683 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,750,000 repurchased shares. Consequently, the total number of shares in issue has been adjusted to 5,503,563,683. The filing does not report material changes to operational performance or financial position compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the updated share count of 5,503,563,683 for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the total Treasury share holding of 504,194,158 shares, which represents 9.16% of voting rights.
- Note that this filing is a notification of a completed share buyback and does not contain quarterly or annual financial results.